Philippe Lambin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1418477/publications.pdf

Version: 2024-02-01

495 46,459 94 192 g-index

512 512 512 512 34839

times ranked

citing authors

docs citations

all docs

#	Article	IF	CITATIONS
1	Radiomics: Extracting more information from medical images using advanced feature analysis. European Journal of Cancer, 2012, 48, 441-446.	1.3	3,846
2	Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nature Communications, 2014, 5, 4006.	5.8	3,355
3	Radiomics: the bridge between medical imaging and personalized medicine. Nature Reviews Clinical Oncology, 2017, 14, 749-762.	12.5	3,216
4	The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping. Radiology, 2020, 295, 328-338.	3.6	1,869
5	Radiomics: the process and the challenges. Magnetic Resonance Imaging, 2012, 30, 1234-1248.	1.0	1,675
6	Imaging biomarker roadmap for cancer studies. Nature Reviews Clinical Oncology, 2017, 14, 169-186.	12.5	792
7	Machine Learning methods for Quantitative Radiomic Biomarkers. Scientific Reports, 2015, 5, 13087.	1.6	744
8	The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. Journal of Clinical Investigation, 2010, 120, 127-141.	3.9	675
9	CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma. Radiotherapy and Oncology, 2015, 114, 345-350.	0.3	576
10	Robust Radiomics Feature Quantification Using Semiautomatic Volumetric Segmentation. PLoS ONE, 2014, 9, e102107.	1.1	488
11	Nomograms for Predicting Local Recurrence, Distant Metastases, and Overall Survival for Patients With Locally Advanced Rectal Cancer on the Basis of European Randomized Clinical Trials. Journal of Clinical Oncology, 2011, 29, 3163-3172.	0.8	439
12	Selection of patients for radiotherapy with protons aiming at reduction of side effects: The model-based approach. Radiotherapy and Oncology, 2013, 107, 267-273.	0.3	408
13	A literature review of electronic portal imaging for radiotherapy dosimetry. Radiotherapy and Oncology, 2008, 88, 289-309.	0.3	384
14	Radiomic feature clusters and Prognostic Signatures specific for Lung and Head & Deck cancer. Scientific Reports, 2015, 5, 11044.	1.6	384
15	Stability of FDG-PET Radiomics features: An integrated analysis of test-retest and inter-observer variability. Acta Oncológica, 2013, 52, 1391-1397.	0.8	353
16	Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy 18Fluorodeoxyglucose-PET-CT scan. Radiotherapy and Oncology, 2009, 91, 386-392.	0.3	340
17	Predicting outcomes in radiation oncologyâ€"multifactorial decision support systems. Nature Reviews Clinical Oncology, 2013, 10, 27-40.	12.5	329
18	Gene expression during acute and prolonged hypoxia is regulated by distinct mechanisms of translational control. EMBO Journal, 2006, 25, 1114-1125.	3.5	328

#	Article	IF	CITATIONS
19	The effect of SUV discretization in quantitative FDG-PET Radiomics: the need for standardized methodology in tumor texture analysis. Scientific Reports, 2015, 5, 11075.	1.6	318
20	Radiomic Machine-Learning Classifiers for Prognostic Biomarkers of Head and Neck Cancer. Frontiers in Oncology, 2015, 5, 272.	1.3	318
21	Exploratory Study to Identify Radiomics Classifiers for Lung Cancer Histology. Frontiers in Oncology, 2016, 6, 71.	1.3	306
22	Time Between the First Day of Chemotherapy and the Last Day of Chest Radiation Is the Most Important Predictor of Survival in Limited-Disease Small-Cell Lung Cancer. Journal of Clinical Oncology, 2006, 24, 1057-1063.	0.8	301
23	Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: A meta-analysis. Radiotherapy and Oncology, 2010, 95, 32-40.	0.3	295
24	PET-CT–Based Auto-Contouring in Non–Small-Cell Lung Cancer Correlates With Pathology and Reduces Interobserver Variability in the Delineation of the Primary Tumor and Involved Nodal Volumes. International Journal of Radiation Oncology Biology Physics, 2007, 68, 771-778.	0.4	274
25	Quantitative radiomics studies for tissue characterization: a review of technology and methodological procedures. British Journal of Radiology, 2017, 90, 20160665.	1.0	270
26	Defining the biological basis of radiomic phenotypes in lung cancer. ELife, 2017, 6, .	2.8	258
27	Radical Treatment of Non–Small-Cell Lung Cancer Patients with Synchronous Oligometastases: Long-Term Results of a Prospective Phase II Trial (Nct01282450). Journal of Thoracic Oncology, 2012, 7, 1547-1555.	0.5	251
28	Machine learning algorithms for outcome prediction in (chemo)radiotherapy: An empirical comparison of classifiers. Medical Physics, 2018, 45, 3449-3459.	1.6	214
29	E-Cadherin loss associated with EMT promotes radioresistance in human tumor cells. Radiotherapy and Oncology, 2011, 99, 392-397.	0.3	210
30	Quantitative Computed Tomographic Descriptors Associate Tumor Shape Complexity and Intratumor Heterogeneity with Prognosis in Lung Adenocarcinoma. PLoS ONE, 2015, 10, e0118261.	1.1	207
31	Selective mediastinal node irradiation based on FDG-PET scan data in patients with non–small-cell lung cancer: A prospective clinical study. International Journal of Radiation Oncology Biology Physics, 2005, 62, 988-994.	0.4	202
32	External validation of a prognostic CT-based radiomic signature in oropharyngeal squamous cell carcinoma. Acta Oncol \hat{A}^3 gica, 2015, 54, 1423-1429.	0.8	195
33	PERK/eIF2α signaling protects therapy resistant hypoxic cells through induction of glutathione synthesis and protection against ROS. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 4622-4627.	3.3	193
34	The maximum uptake of 18F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor- $\hat{\Pi}\pm$ and GLUT-1 in non-small cell lung cancer. European Journal of Cancer, 2007, 43, 1392-1398.	1.3	188
35	Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model. Radiotherapy and Oncology, 2009, 92, 423-428.	0.3	185
36	Influence of gray level discretization on radiomic feature stability for different CT scanners, tube currents and slice thicknesses: a comprehensive phantom study. Acta Oncológica, 2017, 56, 1544-1553.	0.8	183

#	Article	IF	Citations
37	Disparity Between In Vivo EGFR Expression and ⁸⁹ Zr-Labeled Cetuximab Uptake Assessed with PET. Journal of Nuclear Medicine, 2009, 50, 123-131.	2.8	180
38	Targeting Hypoxia to Improve Non–Small Cell Lung Cancer Outcome. Journal of the National Cancer Institute, 2018, 110, 14-30.	3.0	177
39	â€~Rapid Learning health care in oncology' – An approach towards decision support systems enabling customised radiotherapy'. Radiotherapy and Oncology, 2013, 109, 159-164.	0.3	175
40	Tracking tumor biology with radiomics: A systematic review utilizing a radiomics quality score. Radiotherapy and Oncology, 2018, 127, 349-360.	0.3	175
41	Development of a Clinical Decision Support System for Severity Risk Prediction and Triage of COVID-19 Patients at Hospital Admission: an International Multicenter Study. European Respiratory Journal, 2020, 56, 2001104.	3.1	172
42	Tumor perfusion rate determined noninvasively by dynamic computed tomography predicts outcome in head-and-neck cancer after radiotherapy. International Journal of Radiation Oncology Biology Physics, 2003, 57, 1351-1356.	0.4	169
43	Volumetric CT-based segmentation of NSCLC using 3D-Slicer. Scientific Reports, 2013, 3, 3529.	1.6	168
44	Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies. Journal of Enzyme Inhibition and Medicinal Chemistry, 2009, 24, 1-39.	2.5	167
45	Selective Nodal Irradiation on Basis of 18FDG-PET Scans in Limited-Disease Small-Cell Lung Cancer: A Prospective Study. International Journal of Radiation Oncology Biology Physics, 2010, 77, 329-336.	0.4	166
46	How costly is particle therapy? Cost analysis of external beam radiotherapy with carbon-ions, protons and photons. Radiotherapy and Oncology, 2010, 95, 45-53.	0.3	166
47	Oxygenation of head and neck tumors. Cancer, 1993, 71, 2319-2325.	2.0	164
48	Radiomics: from qualitative to quantitative imaging. British Journal of Radiology, 2020, 93, 20190948.	1.0	164
49	Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors. Radiotherapy and Oncology, 2007, 83, 367-373.	0.3	157
50	Mature Results of an Individualized Radiation Dose Prescription Study Based on Normal Tissue Constraints in Stages I to III Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2010, 28, 1380-1386.	0.8	156
51	Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. Radiotherapy and Oncology, 2011, 99, 424-431.	0.3	156
52	Accurate Automatic Delineation of Heterogeneous Functional Volumes in Positron Emission Tomography for Oncology Applications. International Journal of Radiation Oncology Biology Physics, 2010, 77, 301-308.	0.4	154
53	The current status of FDG–PET in tumour volume definition in radiotherapy treatment planning. Cancer Treatment Reviews, 2006, 32, 245-260.	3.4	153
54	Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non–small-cell lung cancer: A modeling study. International Journal of Radiation Oncology Biology Physics, 2005, 61, 649-655.	0.4	151

#	Article	IF	Citations
55	Monitoring myeloablative therapy-induced small bowel toxicity by serum citrulline concentration. Cancer, 2005, 103, 191-199.	2.0	145
56	A Comparative Study of the Hypoxia PET Tracers [18F]HX4, [18F]FAZA, and [18F]FMISO in a Preclinical Tumor Model. International Journal of Radiation Oncology Biology Physics, 2015, 91, 351-359.	0.4	139
57	Distributed learning: Developing a predictive model based on data from multiple hospitals without data leaving the hospital – A real life proof of concept. Radiotherapy and Oncology, 2016, 121, 459-467.	0.3	139
58	Automated delineation of lung tumors from CT images using a single click ensemble segmentation approach. Pattern Recognition, 2013, 46, 692-702.	5.1	138
59	Functional MRI for radiotherapy dose painting. Magnetic Resonance Imaging, 2012, 30, 1216-1223.	1.0	136
60	Survival prediction of non-small cell lung cancer patients using radiomics analyses of cone-beam CT images. Radiotherapy and Oncology, 2017, 123, 363-369.	0.3	136
61	Effects of radiotherapy planning with a dedicated combined PET-CT-simulator of patients with non-small cell lung cancer on dose limiting normal tissues and radiation dose-escalation: A planning study. Radiotherapy and Oncology, 2005, 77, 5-10.	0.3	135
62	Test–Retest Data for Radiomics Feature Stability Analysis: Generalizable or Study-Specific?. Tomography, 2016, 2, 361-365.	0.8	135
63	Timing of chest radiotherapy in patients with limited stage small cell lung cancer: A systematic review and meta-analysis of randomised controlled trials. Cancer Treatment Reviews, 2007, 33, 461-473.	3.4	133
64	Transparency of deep neural networks for medical image analysis: A review of interpretability methods. Computers in Biology and Medicine, 2022, 140, 105111.	3.9	131
65	Autophagy is required during cycling hypoxia to lower production of reactive oxygen species. Radiotherapy and Oncology, 2009, 92, 411-416.	0.3	130
66	Prognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-Analysis. Frontiers in Oncology, 2016, 6, 69.	1.3	129
67	Dynamic contrast-enhanced magnetic resonance imaging of radiation therapy-induced microcirculation changes in rectal cancer. International Journal of Radiation Oncology Biology Physics, 2005, 63, 1309-1315.	0.4	128
68	Impact of Tumor Size and Tracer Uptake Heterogeneity in ¹⁸ F-FDG PET and CT Non–Small Cell Lung Cancer Tumor Delineation. Journal of Nuclear Medicine, 2011, 52, 1690-1697.	2.8	126
69	Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer: A phase II trial. Radiotherapy and Oncology, 2006, 80, 307-312.	0.3	123
70	Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14620-14625.	3.3	121
71	Citrulline: A physiologic marker enabling quantitation and monitoring of epithelial radiation-induced small bowel damage. International Journal of Radiation Oncology Biology Physics, 2003, 57, 1067-1074.	0.4	120
72	Preservation of parotid function with uncomplicated conformal radiotherapy. Radiotherapy and Oncology, 2002, 63, 203-211.	0.3	115

#	Article	IF	CITATIONS
73	Plasma citrulline concentration: A surrogate end point for radiation-induced mucosal atrophy of the small bowel. A feasibility study in 23 patients. International Journal of Radiation Oncology Biology Physics, 2004, 60, 275-285.	0.4	113
74	Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer. BMC Cancer, 2013, 13, 84.	1.1	113
75	Decision support systems for personalized and participative radiation oncology. Advanced Drug Delivery Reviews, 2017, 109, 131-153.	6.6	113
76	Lysine 63-Polyubiquitination Guards against Translesion Synthesis–Induced Mutations. PLoS Genetics, 2006, 2, e116.	1.5	109
77	Optimal gating compared to 3D and 4D PET reconstruction for characterization of lung tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 843-855.	3.3	109
78	Development and validation of a radiomic signature to predict HPV (p16) status from standard CT imaging: a multicenter study. British Journal of Radiology, 2018, 91, 20170498.	1.0	109
79	Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms. Oncotarget, 2018, 9, 16932-16950.	0.8	109
80	Early improvements in vision after fractionated stereotactic radiotherapy for primary optic nerve sheath meningioma. Radiotherapy and Oncology, 2004, 72, 169-174.	0.3	106
81	Response Assessment Using ¹⁸ F-FDG PET Early in the Course of Radiotherapy Correlates with Survival in Advanced-Stage Non–Small Cell Lung Cancer. Journal of Nuclear Medicine, 2012, 53, 1514-1520.	2.8	106
82	Is there a causal relationship between genetic changes and radiomics-based image features? An in vivo preclinical experiment with doxycycline inducible GADD34 tumor cells. Radiotherapy and Oncology, 2015, 116, 462-466.	0.3	106
83	The hypoxic proteome is influenced by gene-specific changes in mRNA translation. Radiotherapy and Oncology, 2005, 76, 177-186.	0.3	105
84	Intra-patient variability of tumor volume and tumor motion during conventionally fractionated radiotherapy for locally advanced non-small-cell lung cancer: A prospective clinical study. International Journal of Radiation Oncology Biology Physics, 2006, 66, 748-753.	0.4	105
85	The Quest for Evidence for Proton Therapy: Model-Based Approach and Precision Medicine. International Journal of Radiation Oncology Biology Physics, 2016, 95, 30-36.	0.4	105
86	A review in radiomics: Making personalized medicine a reality via routine imaging. Medicinal Research Reviews, 2022, 42, 426-440.	5.0	103
87	Developing and Validating a Survival Prediction Model for NSCLC Patients Through Distributed Learning Across 3 Countries. International Journal of Radiation Oncology Biology Physics, 2017, 99, 344-352.	0.4	102
88	Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy. A prospective study in locally advanced non-small cell lung cancer (NSCLC) patients. Radiotherapy and Oncology, 2007, 82, 145-152.	0.3	101
89	Tumor Volume Combined With Number of Positive Lymph Node Stations Is a More Important Prognostic Factor Than TNM Stage for Survival of Non–Small-Cell Lung Cancer Patients Treated With (Chemo)radiotherapy. International Journal of Radiation Oncology Biology Physics, 2008, 70, 1039-1044.	0.4	101
90	PET imaging of hypoxia using [18F]HX4: a phase I trial. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1663-1668.	3.3	100

#	Article	IF	Citations
91	A semiautomatic CT-based ensemble segmentation of lung tumors: Comparison with oncologists' delineations and with the surgical specimen. Radiotherapy and Oncology, 2012, 105, 167-173.	0.3	99
92	Combining radiotherapy with immunotherapy: the past, the present and the future. British Journal of Radiology, 2017, 90, 20170157.	1.0	99
93	Infrastructure and distributed learning methodology for privacy-preserving multi-centric rapid learning health care: euroCAT. Clinical and Translational Radiation Oncology, 2017, 4, 24-31.	0.9	98
94	Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum. Cancer Gene Therapy, 2001, 8, 294-297.	2.2	97
95	Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: A prospective validation. Lung Cancer, 2012, 75, 73-76.	0.9	97
96	Distributed learning on 20 000+ lung cancer patients – The Personal Health Train. Radiotherapy and Oncology, 2020, 144, 189-200.	0.3	97
97	TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging. Clinical Cancer Research, 2015, 21, 2984-2992.	3.2	95
98	Biomarkers for radiation-induced small bowel epithelial damage: An emerging role for plasma Citrulline. World Journal of Gastroenterology, 2007, 13, 3033.	1.4	95
99	The impact of late treatment-toxicity on generic health-related quality of life in head and neck cancer patients after radiotherapy. Oral Oncology, 2011, 47, 768-774.	0.8	94
100	Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium. Journal of Enzyme Inhibition and Medicinal Chemistry, 2015, 30, 689-721.	2.5	93
101	Stability of radiomics features in apparent diffusion coefficient maps from a multi-centre test-retest trial. Scientific Reports, 2019, 9, 4800.	1.6	93
102	Predictive and prognostic value of CT based radiomics signature in locally advanced head and neck cancers patients treated with concurrent chemoradiotherapy or bioradiotherapy and its added value to Human Papillomavirus status. Oral Oncology, 2017, 71, 150-155.	0.8	92
103	Modulation of cell death in the tumor microenvironment. Seminars in Radiation Oncology, 2003, 13, 31-41.	1.0	91
104	Routine individualised patient dosimetry using electronic portal imaging devices. Radiotherapy and Oncology, 2007, 83, 65-75.	0.3	91
105	Fractal-based radiomic approach to predict complete pathological response after chemo-radiotherapy in rectal cancer. Radiologia Medica, 2018, 123, 286-295.	4.7	91
106	Development and external validation of a predictive model for pathological complete response of rectal cancer patients including sequential PET-CT imaging. Radiotherapy and Oncology, 2011, 98, 126-133.	0.3	89
107	Results of a Multicentric In Silico Clinical Trial (ROCOCO): Comparing Radiotherapy with Photons and Protons for Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 165-176.	0.5	89
108	Is high-dose stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC) overkill? A systematic review. Radiotherapy and Oncology, 2012, 105, 145-149.	0.3	89

#	Article	IF	CITATIONS
109	Post-radiochemotherapy PET radiomics in head and neck cancer – The influence of radiomics implementation on the reproducibility of local control tumor models. Radiotherapy and Oncology, 2017, 125, 385-391.	0.3	89
110	Chronic radiation proctitis: tricks to prevent and treat. International Journal of Colorectal Disease, 2015, 30, 1293-1303.	1.0	87
111	Systematic review and meta-analysis of radiotherapy in various head and neck cancers: Comparing photons, carbon-ions and protons. Cancer Treatment Reviews, 2011, 37, 185-201.	3.4	86
112	A Deep Look Into the Future of Quantitative Imaging in Oncology: A Statement of Working Principles and Proposal for Change. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1074-1082.	0.4	86
113	Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials. Clinical and Translational Radiation Oncology, 2019, 15, 62-69.	0.9	86
114	Dose–response relationships within the parotid gland after radiotherapy for head and neck cancer. Radiotherapy and Oncology, 2004, 73, 297-306.	0.3	85
115	The importance of patient characteristics for the prediction of radiation-induced lung toxicity. Radiotherapy and Oncology, 2009, 91, 421-426.	0.3	85
116	Decision Support Systems in Oncology. JCO Clinical Cancer Informatics, 2019, 3, 1-9.	1.0	85
117	In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. International Journal of Radiation Oncology Biology Physics, 2001, 49, 443-450.	0.4	83
118	The next step in patient-specific QA: 3D dose verification of conformal and intensity-modulated RT based on EPID dosimetry and Monte Carlo dose calculations. Radiotherapy and Oncology, 2008, 86, 86-92.	0.3	83
119	A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients. International Journal of Radiation Oncology Biology Physics, 2015, 92, 935-944.	0.4	83
120	MRI-guided Radiation Therapy: An Emerging Paradigm in Adaptive Radiation Oncology. Radiology, 2021, 298, 248-260.	3.6	83
121	18FDG-PET based radiation planning of mediastinal lymph nodes in limited disease small cell lung cancer changes radiotherapy fields: A planning study. Radiotherapy and Oncology, 2008, 87, 49-54.	0.3	82
122	Development and External Validation of Prognostic Model for 2-Year Survival of Non–Small-Cell Lung Cancer Patients Treated With Chemoradiotherapy. International Journal of Radiation Oncology Biology Physics, 2009, 74, 355-362.	0.4	82
123	Synthesis and biological evaluation of a 99mTc-labelled sulfonamide conjugate for in vivo visualization of carbonic anhydrase IX expression in tumor hypoxia. Nuclear Medicine and Biology, 2010, 37, 557-564.	0.3	82
124	Targeting hypoxia tolerance in cancer. Drug Resistance Updates, 2004, 7, 25-40.	6.5	81
125	Development of a flexible and potent hypoxia-inducible promoter for tumor-targeted gene expression in attenuated s <i>almonella</i> classinglia> li>almonellaclassinglia> li>almonella	1.5	81
126	Stability of 18F-Deoxyglucose Uptake Locations Within Tumor During Radiotherapy for NSCLC: A Prospective Study. International Journal of Radiation Oncology Biology Physics, 2008, 71, 1402-1407.	0.4	81

#	Article	IF	CITATIONS
127	Hypoxia imaging with [18F]HX4 PET in NSCLC patients: Defining optimal imaging parameters. Radiotherapy and Oncology, 2013, 109, 58-64.	0.3	81
128	<i>In Vivo</i> Quantification of Hypoxic and Metabolic Status of NSCLC Tumors Using [18F]HX4 and [18F]FDG-PET/CT Imaging. Clinical Cancer Research, 2014, 20, 6389-6397.	3.2	81
129	Magnetic Resonance, Vendor-independent, Intensity Histogram Analysis Predicting Pathologic Complete Response After Radiochemotherapy of Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 102, 765-774.	0.4	81
130	Deep learning in fracture detection: a narrative review. Monthly Notices of the Royal Astronomical Society: Letters, 2020, 91, 215-220.	1.2	81
131	Impact of supervised gene signatures of early hypoxia on patient survival. Radiotherapy and Oncology, 2007, 83, 374-382.	0.3	80
132	Patient satisfaction with nurse-led telephone follow-up after curative treatment for breast cancer. BMC Cancer, 2010, 10, 174.	1,1	80
133	Targeting carbonic anhydrase IX by nitroimidazole based sulfamides enhances the therapeutic effect of tumor irradiation: A new concept of dual targeting drugs. Radiotherapy and Oncology, 2013, 108, 523-528.	0.3	80
134	Creating a data exchange strategy for radiotherapy research: Towards federated databases and anonymised public datasets. Radiotherapy and Oncology, 2014, 113, 303-309.	0.3	79
135	Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects. Clinical Cancer Research, 2015, 21, 1151-1160.	3.2	79
136	Potential role for low dose limited-field radiation therapy (2 \tilde{A} — 2 grays) in advanced low-grade non-Hodgkin's lymphomas. Hematological Oncology, 1994, 12, 1-8.	0.8	78
137	Improving the quality and efficiency of follow-up after curative treatment for breast cancer – rationale and study design of the MaCare trial. BMC Cancer, 2007, 7, 1.	1.1	78
138	Health-related quality of life in patients surviving non-small cell lung cancer. Thorax, 2010, 65, 903-907.	2.7	77
139	A prospective study comparing the predictions of doctors versus models for treatment outcome of lung cancer patients: A step toward individualized care and shared decision making. Radiotherapy and Oncology, 2014, 112, 37-43.	0.3	77
140	Accurate Prediction of Pathological Rectal Tumor Response after Two Weeks of Preoperative Radiochemotherapy Using 18F-Fluorodeoxyglucose-Positron Emission Tomography-Computed Tomography Imaging. International Journal of Radiation Oncology Biology Physics, 2010, 77, 392-399.	0.4	76
141	Hypoxia-Targeting Carbonic Anhydrase IX Inhibitors by a New Series of Nitroimidazole-Sulfonamides/Sulfamides/Sulfamates. Journal of Medicinal Chemistry, 2013, 56, 8512-8520.	2.9	76
142	Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro in v	0.8	76
143	Does sucralfate reduce the acute side-effects in head and neck cancer treated with radiotherapy? A double-blind randomized trial. Radiotherapy and Oncology, 1998, 47, 149-153.	0.3	75
144	Tumoural perfusion as measured by dynamic computed tomography in head and neck carcinoma. Radiotherapy and Oncology, 1999, 53, 105-111.	0.3	75

#	Article	IF	Citations
145	Evaluation of nonrigid registration models for interfraction dose accumulation in radiotherapy. Medical Physics, 2009, 36, 4268-4276.	1.6	73
146	The ESTRO Breur Lecture 2009. From population to voxel-based radiotherapy: Exploiting intra-tumour and intra-organ heterogeneity for advanced treatment of non-small cell lung cancer. Radiotherapy and Oncology, 2010, 96, 145-152.	0.3	72
147	Externally validated HPV-based prognostic nomogram for oropharyngeal carcinoma patients yields more accurate predictions than TNM staging. Radiotherapy and Oncology, 2014, 113, 324-330.	0.3	72
148	Systematic Review of Privacy-Preserving Distributed Machine Learning From Federated Databases in Health Care. JCO Clinical Cancer Informatics, 2020, 4, 184-200.	1.0	72
149	Making Radiomics More Reproducible across Scanner and Imaging Protocol Variations: A Review of Harmonization Methods. Journal of Personalized Medicine, 2021, 11, 842.	1.1	72
150	3D In Vivo Dosimetry Using Megavoltage Cone-Beam CT and EPID Dosimetry. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1580-1587.	0.4	71
151	Protons in Head-and-Neck Cancer: Bridging the Gap of Evidence. International Journal of Radiation Oncology Biology Physics, 2013, 85, 1282-1288.	0.4	71
152	Development, external validation and clinical usefulness of a practical prediction model for radiation-induced dysphagia in lung cancer patients. Radiotherapy and Oncology, 2010, 97, 455-461.	0.3	70
153	Secretory production of biologically active rat interleukin-2 byClostridium acetobutylicumDSM792 as a tool for anti-tumor treatment. FEMS Microbiology Letters, 2005, 246, 67-73.	0.7	69
154	[18F]fluorodeoxyglucose Uptake Patterns in Lung Before Radiotherapy Identify Areas More Susceptible to Radiation-Induced Lung Toxicity in Non-Small-Cell Lung Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2011, 81, 698-705.	0.4	67
155	International data-sharing for radiotherapy research: An open-source based infrastructure for multicentric clinical data mining. Radiotherapy and Oncology, 2014, 110, 370-374.	0.3	67
156	Radiation Dose Prescription for Non–Small-Cell Lung Cancer According to Normal Tissue Dose Constraints: An In Silico Clinical Trial. International Journal of Radiation Oncology Biology Physics, 2008, 71, 1103-1110.	0.4	66
157	Correlation of intra-tumour heterogeneity on 18F-FDG PET with pathologic features in non-small cell lung cancer: A feasibility study. Radiotherapy and Oncology, 2008, 87, 55-58.	0.3	66
158	Mature results of a phase II trial on individualised accelerated radiotherapy based on normal tissue constraints in concurrent chemo-radiation for stage III non-small cell lung cancer. European Journal of Cancer, 2012, 48, 2339-2346.	1,3	65
159	Development and evaluation of an online three-level proton vs photon decision support prototype for head and neck cancer – Comparison of dose, toxicity and cost-effectiveness. Radiotherapy and Oncology, 2016, 118, 281-285.	0.3	65
160	Tumour delineation and cumulative dose computation in radiotherapy based on deformable registration of respiratory correlated CT images of lung cancer patients. Radiotherapy and Oncology, 2007, 85, 232-238.	0.3	64
161	Increased 18F-deoxyglucose uptake in the lung during the first weeks of radiotherapy is correlated with subsequent Radiation-Induced Lung Toxicity (RILT): A prospective pilot study. Radiotherapy and Oncology, 2009, 91, 415-420.	0.3	64
162	PET-based dose painting in non-small cell lung cancer: Comparing uniform dose escalation with boosting hypoxic and metabolically active sub-volumes. Radiotherapy and Oncology, 2015, 116, 281-286.	0.3	64

#	Article	IF	CITATIONS
163	Multiparametric imaging of patient and tumour heterogeneity in non-small-cell lung cancer: quantification of tumour hypoxia, metabolism and perfusion. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 240-248.	3.3	64
164	Diagnosis of Invasive Lung Adenocarcinoma Based on Chest CT Radiomic Features of Part-Solid Pulmonary Nodules: A Multicenter Study. Radiology, 2020, 297, 451-458.	3.6	64
165	A Monte Carlo based three-dimensional dose reconstruction method derived from portal dose images. Medical Physics, 2006, 33, 2426-2434.	1.6	63
166	Radiation-induced bullous pemphigoid: A systematic review of an unusual radiation side effect. Radiotherapy and Oncology, 2007, 82, 5-9.	0.3	63
167	Development and validation of a nomogram for prediction of survival and local control in laryngeal carcinoma patients treated with radiotherapy alone: A cohort study based on 994 patients. Radiotherapy and Oncology, 2011, 100, 108-115.	0.3	62
168	Benefits of a clinical data warehouse with data mining tools to collect data for a radiotherapy trial. Radiotherapy and Oncology, 2013, 108, 174-179.	0.3	62
169	Data harmonisation for information fusion in digital healthcare: A state-of-the-art systematic review, meta-analysis and future research directions. Information Fusion, 2022, 82, 99-122.	11.7	62
170	Development and Validation of a Prognostic Model Using Blood Biomarker Information for Prediction of Survival of Non–Small-Cell Lung Cancer Patients Treated With Combined Chemotherapy and Radiation or Radiotherapy Alone (NCT00181519, NCT00573040, and NCT00572325). International Journal of Radiation Oncology Biology Physics, 2011, 81, 360-368.	0.4	61
171	4DCT imaging to assess radiomics feature stability: An investigation for thoracic cancers. Radiotherapy and Oncology, 2017, 125, 147-153.	0.3	61
172	High NOTCH activity induces radiation resistance in non small cell lung cancer. Radiotherapy and Oncology, 2013, 108, 440-445.	0.3	60
173	Magnetic Resonance Guided High-Intensity Focused Ultrasound Mediated Hyperthermia Improves the Intratumoral Distribution of Temperature-Sensitive Liposomal Doxorubicin. Investigative Radiology, 2013, 48, 395-405.	3.5	60
174	Modern clinical research: How rapid learning health care and cohort multiple randomised clinical trials complement traditional evidence based medicine. Acta Oncológica, 2015, 54, 1289-1300.	0.8	59
175	Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase IB trial. Autophagy, 2021, 17, 2604-2612.	4.3	59
176	Pre-treatment CT radiomics to predict 3-year overall survival following chemoradiotherapy of esophageal cancer. Acta Oncol \tilde{A}^3 gica, 2018, 57, 1475-1481.	0.8	58
177	Individualized Radical Radiotherapy of Non–Small-Cell Lung Cancer Based on Normal Tissue Dose Constraints: A Feasibility Study. International Journal of Radiation Oncology Biology Physics, 2008, 71, 1394-1401.	0.4	57
178	Hypoxia-induced Expression of Carbonic Anhydrase 9 Is Dependent on the Unfolded Protein Response. Journal of Biological Chemistry, 2009, 284, 24204-24212.	1.6	57
179	The cost-effectiveness of particle therapy in non-small cell lung cancer: Exploring decision uncertainty and areas for future research. Cancer Treatment Reviews, 2010, 36, 468-476.	3.4	57
180	18F-fluorodeoxyglucose positron-emission tomography (FDG-PET)-Radiomics of metastatic lymph nodes and primary tumor in non-small cell lung cancer (NSCLC) $\hat{a} \in \text{``A prospective externally validated study.}$ PLoS ONE, 2018, 13, e0192859.	1.1	57

#	Article	IF	Citations
181	Lymphocyte-Sparing Radiotherapy: The Rationale for Protecting Lymphocyte-rich Organs When Combining Radiotherapy With Immunotherapy. Seminars in Radiation Oncology, 2020, 30, 187-193.	1.0	57
182	Reversal of Hypoxia in Murine Atherosclerosis Prevents Necrotic Core Expansion by Enhancing Efferocytosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 2545-2553.	1.1	56
183	Prone breast irradiation for pendulous breasts. Radiotherapy and Oncology, 2007, 82, 337-340.	0.3	55
184	Intra-voxel heterogeneity influences the dose prescription for dose-painting with radiotherapy: a modelling study. Physics in Medicine and Biology, 2009, 54, 2179-2196.	1.6	55
185	Repeatability of hypoxia PET imaging using [18F]HX4 in lung and head and neck cancer patients: a prospective multicenter trial. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1840-1849.	3.3	55
186	Feature selection methodology for longitudinal cone-beam CT radiomics. Acta Oncol \tilde{A}^3 gica, 2017, 56, 1537-1543.	0.8	55
187	Phosphorylation of eIF2α is required for mRNA translation inhibition and survival during moderate hypoxia. Radiotherapy and Oncology, 2007, 83, 353-361.	0.3	54
188	Particle Therapy for Non-Small Cell Lung Tumors: Where Do We Stand? A Systematic Review of the Literature. Frontiers in Oncology, 2014, 4, 292.	1.3	54
189	Metabolic control probability in tumour subvolumes or how to guide tumour dose redistribution in non-small cell lung cancer (NSCLC): An exploratory clinical study. Radiotherapy and Oncology, 2009, 91, 393-398.	0.3	53
190	Follow-up after treatment for breast cancer: One strategy fits all? An investigation of patient preferences using a discrete choice experiment. Acta Oncológica, 2010, 49, 328-337.	0.8	53
191	FDG–PET–CT reduces the interobserver variability in rectal tumor delineation. Radiotherapy and Oncology, 2012, 102, 371-376.	0.3	53
192	The integration of PET-CT scans from different hospitals into radiotherapy treatment planning. Radiotherapy and Oncology, 2008, 87, 142-146.	0.3	52
193	What to choose as radical local treatment for lung metastases from colo-rectal cancer: Surgery or radiofrequency ablation?. Cancer Treatment Reviews, 2014, 40, 60-67.	3.4	52
194	FDG-PET provides the best correlation with the tumor specimen compared to MRI and CT in rectal cancer. Radiotherapy and Oncology, 2011, 98, 270-276.	0.3	51
195	Nomogram predicting response after chemoradiotherapy in rectal cancer using sequential PETCT imaging: A multicentric prospective study with external validation. Radiotherapy and Oncology, 2014, 113, 215-222.	0.3	51
196	Evaluation of tumour hypoxia during radiotherapy using [18F]HX4 PET imaging and blood biomarkers in patients with head and neck cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2139-2146.	3.3	51
197	Follow-up with 18FDG-PET–CT after radical radiotherapy with or without chemotherapy allows the detection of potentially curable progressive disease in non-small cell lung cancer patients: A prospective study. European Journal of Cancer, 2009, 45, 588-595.	1.3	50
198	The prognostic value of temporal in vitro and in vivo derived hypoxia gene-expression signatures in breast cancer. Radiotherapy and Oncology, 2012, 102, 436-443.	0.3	50

#	Article	IF	Citations
199	Cardiac comorbidity is an independent risk factor for radiation-induced lung toxicity in lung cancer patients. Radiotherapy and Oncology, 2013, 109, 100-106.	0.3	50
200	Early versus late chest radiotherapy in patients with limited-stage small cell lung cancer. The Cochrane Library, 2004, , CD004700.	1.5	49
201	The Use of FDG-PET to Target Tumors by Radiotherapy. Strahlentherapie Und Onkologie, 2010, 186, 471-481.	1.0	49
202	Selection of appropriate end-points (pCR vs 2yDFS) for tailoring treatments with prediction models in locally advanced rectal cancer. Radiotherapy and Oncology, 2015, 114 , $302-309$.	0.3	49
203	Spacers in radiotherapy treatment of prostate cancer: Is reduction of toxicity cost-effective?. Radiotherapy and Oncology, 2015, 114, 276-281.	0.3	49
204	New ways to image and target tumour hypoxia and its molecular responses. Radiotherapy and Oncology, 2015, 116, 352-357.	0.3	49
205	Facile fabrication of lightweight porous FDM-Printed polyethylene/graphene nanocomposites with enhanced interfacial strength for electromagnetic interference shielding. Composites Science and Technology, 2021, 207, 108732.	3.8	49
206	Non-invasive tumour perfusion measurement by dynamic CT: preliminary results. Radiotherapy and Oncology, 1997, 44, 159-162.	0.3	48
207	Rapid Point-Of-Care Breath Test for Biomarkers of Breast Cancer and Abnormal Mammograms. PLoS ONE, 2014, 9, e90226.	1.1	48
208	PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer. Radiotherapy and Oncology, 2017, 122, 267-273.	0.3	48
209	Longitudinal radiomics of cone-beam CT images from non-small cell lung cancer patients: Evaluation of the added prognostic value for overall survival and locoregional recurrence. Radiotherapy and Oncology, 2019, 136, 78-85.	0.3	48
210	Structural and functional radiomics for lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3961-3974.	3.3	48
211	Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach. Oncotarget, 2017, 8, 3870-3880.	0.8	48
212	Vascular targeting effect of combretastatin A-4 phosphate dominates the inherent angiogenesis inhibitory activity. International Journal of Cancer, 2003, 105, 20-25.	2.3	46
213	Expression of EGFR variant vIII promotes both radiation resistance and hypoxia tolerance. Radiotherapy and Oncology, 2007, 83, 333-339.	0.3	46
214	18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: An economic evaluation. European Journal of Cancer, 2010, 46, 110-119.	1.3	46
215	Benefit of particle therapy in re-irradiation of head and neck patients. Results of a multicentric in silico ROCOCO trial. Radiotherapy and Oncology, 2016, 121, 387-394.	0.3	46
216	Privacy-preserving distributed learning of radiomics to predict overall survival and HPV status in head and neck cancer. Scientific Reports, 2020, 10, 4542.	1.6	46

#	Article	IF	Citations
217	The mTOR target 4Eâ€BP1 contributes to differential protein expression during normoxia and hypoxia through changes in mRNA translation efficiency. Proteomics, 2008, 8, 1019-1028.	1.3	45
218	PET-Based Treatment Response Evaluation in Rectal Cancer: Prediction and Validation. International Journal of Radiation Oncology Biology Physics, 2012, 82, 871-876.	0.4	44
219	Prognostic value of metabolic metrics extracted from baseline positron emission tomography images in non-small cell lung cancer. Acta Oncol \tilde{A}^3 gica, 2013, 52, 1398-1404.	0.8	44
220	Prostate Cancer Radiation Therapy: What Do Clinicians Have to Know?. BioMed Research International, 2016, 2016, 1-14.	0.9	44
221	Blockchain for Privacy Preserving and Trustworthy Distributed Machine Learning in Multicentric Medical Imaging (C-DistriM). IEEE Access, 2020, 8, 183939-183951.	2.6	44
222	Automated detection and segmentation of non-small cell lung cancer computed tomography images. Nature Communications, 2022, 13, .	5.8	44
223	Improvement ofClostridiumtumour targeting vectors evaluated in rat rhabdomyosarcomas. FEMS Immunology and Medical Microbiology, 2001, 30, 37-41.	2.7	43
224	Response of U87 glioma xenografts treated with concurrent rapamycin and fractionated radiotherapy: Possible role for thrombosis. Radiotherapy and Oncology, 2007, 82, 96-104.	0.3	43
225	Responsiveness of the EQ-5D in breast cancer patients in their first year after treatment. Health and Quality of Life Outcomes, 2009, 7, 11.	1.0	43
226	Epigenetics in radiotherapy: Where are we heading?. Radiotherapy and Oncology, 2014, 111, 168-177.	0.3	43
227	High-dose radiotherapy or concurrent chemo-radiation in lung cancer patients only induces a temporary, reversible decline in QoL. Radiotherapy and Oncology, 2009, 91, 443-448.	0.3	42
228	Evaluation of early metabolic responses in rectal cancer during combined radiochemotherapy or radiotherapy alone: Sequential FDG-PET-CT findings. Radiotherapy and Oncology, 2010, 94, 151-155.	0.3	42
229	Early CT and FDG-metabolic tumour volume changes show a significant correlation with survival in stage l–III small cell lung cancer: A hypothesis generating study. Radiotherapy and Oncology, 2011, 99, 172-175.	0.3	42
230	Phase I trial of the combination of the Akt inhibitor nelfinavir and chemoradiation for locally advanced rectal cancer. Radiotherapy and Oncology, 2013, 107, 184-188.	0.3	42
231	Blood biomarkers are helpful in the prediction of response to chemoradiation in rectal cancer: A prospective, hypothesis driven study on patients with locally advanced rectal cancer. Radiotherapy and Oncology, 2014, 111, 237-242.	0.3	42
232	Hypoxia and hypoxia response-associated molecular markers in esophageal cancer: A systematic review. Methods, 2017, 130, 51-62.	1.9	42
233	HI-CHART: A Phase I/II Study on the Feasibility of High-Dose Continuous Hyperfractionated Accelerated Radiotherapy in Patients With Inoperable Nonâé"Small-Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 71, 132-138.	0.4	41
234	Rapid learning in practice: A lung cancer survival decision support system in routine patient care data. Radiotherapy and Oncology, 2014, 113, 47-53.	0.3	41

#	Article	IF	Citations
235	Development and biological evaluation of 99mTc-sulfonamide derivatives for inÂvivo visualization of CA IX as surrogate tumor hypoxia markers. European Journal of Medicinal Chemistry, 2014, 71, 374-384.	2.6	41
236	Whole brain radiotherapy versus stereotactic radiosurgery for 4–10 brain metastases: a phase III randomised multicentre trial. BMC Cancer, 2017, 17, 500.	1.1	41
237	Computed Tomography-based Radiomics for Risk Stratification in Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 105, 448-456.	0.4	41
238	An artificial intelligence framework integrating longitudinal electronic health records with real-world data enables continuous pan-cancer prognostication. Nature Cancer, 2021, 2, 709-722.	5.7	41
239	Individualised isotoxic accelerated radiotherapy and chemotherapy are associated with improved long-term survival of patients with stage III NSCLC: A prospective population-based study. Radiotherapy and Oncology, 2012, 102, 228-233.	0.3	40
240	Early prediction of pathological response in locally advanced rectal cancer based on sequential $\langle \sup 18 \rangle$ Sup F-FDG PET. Acta Oncolà gica, 2013, 52, 619-626.	0.8	40
241	[18F]VM4-037 MicroPET Imaging and Biodistribution of Two In Vivo CAIX-Expressing Tumor Models. Molecular Imaging and Biology, 2015, 17, 615-619.	1.3	40
242	Stereotactic Radiosurgery in the Management of Patients With Brain Metastases of Non-Small Cell Lung Cancer: Indications, Decision Tools and Future Directions. Frontiers in Oncology, 2018, 8, 154.	1.3	40
243	Radiomics in Lung Diseases Imaging: State-of-the-Art for Clinicians. Journal of Personalized Medicine, 2021, 11, 602.	1.1	40
244	Fractionated Radiotherapy with 3 \times 8 Gy Induces Systemic Anti-Tumour Responses and Abscopal Tumour Inhibition without Modulating the Humoral Anti-Tumour Response. PLoS ONE, 2016, 11, e0159515.	1.1	40
245	Treatment verification in the presence of inhomogeneities using EPIDâ€based threeâ€dimensional dose reconstruction. Medical Physics, 2007, 34, 2816-2826.	1.6	39
246	Total Body Irradiation, Toward Optimal Individual Delivery: Dose Evaluation With Metal Oxide Field Effect Transistors, Thermoluminescence Detectors, and a Treatment Planning System. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1297-1304.	0.4	39
247	Total Gross Tumor Volume Is an Independent Prognostic Factor in Patients Treated With Selective Nodal Irradiation for Stage I to III Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 85, 1319-1324.	0.4	39
248	Applicability of a prognostic CT-based radiomic signature model trained on stage I-III non-small cell lung cancer in stage IV non-small cell lung cancer. Lung Cancer, 2018, 124, 6-11.	0.9	39
249	Therapeutic implications of molecular imaging with PET in the combined modality treatment of lung cancer. Cancer Treatment Reviews, 2011, 37, 331-343.	3.4	38
250	State of the Art Radiation Therapy for Lung Cancer 2012: A Glimpse of the Future. Clinical Lung Cancer, 2013, 14, 89-95.	1.1	38
251	Radiomics Analysis for Clinical Decision Support in Nuclear Medicine. Seminars in Nuclear Medicine, 2019, 49, 438-449.	2.5	38
252	Challenges and caveats of a multi-center retrospective radiomics study: an example of early treatment response assessment for NSCLC patients using FDG-PET/CT radiomics. PLoS ONE, 2019, 14, e0217536.	1.1	38

#	Article	IF	CITATIONS
253	FDG for dose painting: A rational choice. Radiotherapy and Oncology, 2010, 97, 163-164.	0.3	37
254	Translational control is a major contributor to hypoxia induced gene expression. Radiotherapy and Oncology, 2011, 99, 379-384.	0.3	37
255	miR-210 as a marker of chronic hypoxia, but not a therapeutic target in prostate cancer. Radiotherapy and Oncology, 2011, 101, 203-208.	0.3	37
256	Characterization of tumor heterogeneity using dynamic contrast enhanced CT and FDG-PET in non-small cell lung cancer. Radiotherapy and Oncology, 2013, 109, 65-70.	0.3	37
257	Chemical Reactivity Window Determines Prodrug Efficiency toward Glutathione Transferase Overexpressing Cancer Cells. Molecular Pharmaceutics, 2016, 13, 2010-2025.	2.3	37
258	How Advances in Imaging Will Affect Precision Radiation Oncology. International Journal of Radiation Oncology Biology Physics, 2018, 101, 292-298.	0.4	37
259	Inhibition of 4E-BP1 Sensitizes U87 Glioblastoma Xenograft Tumors to Irradiation by Decreasing Hypoxia Tolerance. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1219-1227.	0.4	36
260	Binding of cetuximab to the EGFRvIII deletion mutant and its biological consequences in malignant glioma cells. Radiotherapy and Oncology, 2009, 92, 393-398.	0.3	36
261	Data-Based Radiation Oncology: Design of Clinical Trials in the Toxicity Biomarkers Era. Frontiers in Oncology, 2017, 7, 83.	1.3	36
262	The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses. Oncolmmunology, 2018, 7, e1414119.	2.1	36
263	Quality Assurance in the EORTC Randomized Trial 22922/10925 Investigating the Role of Irradiation of the Internal Mammary and Medial Supraclavicular Lymph Node Chain Works. Strahlentherapie Und Onkologie, 2006, 182, 576-582.	1.0	35
264	Dyspnea evolution after high-dose radiotherapy in patients with non-small cell lung cancer. Radiotherapy and Oncology, 2009, 91, 353-359.	0.3	35
265	3D dose delivery verification using repeated cone-beam imaging and EPID dosimetry for stereotactic body radiotherapy of non-small cell lung cancer. Radiotherapy and Oncology, 2010, 94, 188-194.	0.3	35
266	Ensemble analyses improve signatures of tumour hypoxia and reveal inter-platform differences. BMC Bioinformatics, 2014, 15, 170.	1.2	35
267	A prediction model for early death in non-small cell lung cancer patients following curative-intent chemoradiotherapy. Acta $Oncol\tilde{A}^3$ gica, 2018, 57, 226-230.	0.8	35
268	Hypoxia PET Imaging with [18F]-HX4â€"A Promising Next-Generation Tracer. Cancers, 2020, 12, 1322.	1.7	35
269	Deep learning for the fully automated segmentation of the inner ear on MRI. Scientific Reports, 2021, 11, 2885.	1.6	35
270	MRI-based delta-radiomics predicts pathologic complete response in high-grade soft-tissue sarcoma patients treated with neoadjuvant therapy. Radiotherapy and Oncology, 2021, 164, 73-82.	0.3	35

#	Article	IF	Citations
271	Computed tomography-derived radiomic signature of head and neck squamous cell carcinoma (peri)tumoral tissue for the prediction of locoregional recurrence and distant metastasis after concurrent chemo-radiotherapy. PLoS ONE, 2020, 15, e0232639.	1.1	35
272	Treatment with curative intent of stage III non-small cell lung cancer patients of 75years: A prospective population-based study. European Journal of Cancer, 2011, 47, 2691-2697.	1.3	34
273	Increasing the Therapeutic Ratio of Stereotactic Ablative Radiotherapy by Individualized Isotoxic Dose Prescription. Journal of the National Cancer Institute, 2016, 108, djv305.	3.0	34
274	Synthesis and in Vivo Biological Evaluation of ⁶⁸ Ga-Labeled Carbonic Anhydrase IX Targeting Small Molecules for Positron Emission Tomography. Journal of Medicinal Chemistry, 2016, 59, 6431-6443.	2.9	33
275	The Emerging Role of Radiomics in COPD and Lung Cancer. Respiration, 2020, 99, 99-107.	1.2	33
276	Design of and technical challenges involved in a framework for multicentric radiotherapy treatment planning studies. Radiotherapy and Oncology, 2010, 97, 567-571.	0.3	32
277	Prognostic value of blood-biomarkers related to hypoxia, inflammation, immune response and tumour load in non-small cell lung cancer – A survival model with external validation. Radiotherapy and Oncology, 2016, 119, 487-494.	0.3	32
278	Standardized data collection to build prediction models in oncology: a prototype for rectal cancer. Future Oncology, 2016, 12, 119-136.	1.1	32
279	[18F]FDG PET radiomics to predict disease-free survival in cervical cancer: a multi-scanner/center study with external validation. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3432-3443.	3.3	32
280	BOLD contrast fMRI of whole rodent tumour during air or carbogen breathing using echo-planar imaging at 1.5 T. European Radiology, 2001, 11, 2332-2340.	2.3	31
281	Psychometric properties of the revised Piper Fatigue Scale in Dutch cancer patients were satisfactory. Journal of Clinical Epidemiology, 2006, 59, 642-649.	2.4	31
282	Tumor Delineation Based on Time–Activity Curve Differences Assessed With Dynamic Fluorodeoxyglucose Positron Emission Tomography–Computed Tomography in Rectal Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2009, 73, 456-465.	0.4	31
283	Tumor perfusion increases during hypofractionated short-course radiotherapy in rectal cancer: Sequential perfusion-CT findings. Radiotherapy and Oncology, 2010, 94, 156-160.	0.3	31
284	The Role of Cancer-Testis Antigens as Predictive and Prognostic Markers in Non-Small Cell Lung Cancer. PLoS ONE, 2013, 8, e67876.	1.1	31
285	Who will benefit most from hydrogel rectum spacer implantation in prostate cancer radiotherapy? A model-based approach for patient selection. Radiotherapy and Oncology, 2016, 121, 118-123.	0.3	31
286	Feasibility of CT radiomics to predict treatment response of individual liver metastases in esophagogastric cancer patients. PLoS ONE, 2018, 13, e0207362.	1,1	31
287	The Effects of In-Plane Spatial Resolution on CT-Based Radiomic Features' Stability with and without ComBat Harmonization. Cancers, 2021, 13, 1848.	1.7	31
288	Development and Validation of an Automated Radiomic CT Signature for Detecting COVID-19. Diagnostics, 2021, 11, 41.	1.3	31

#	Article	IF	Citations
289	Clinical dosimetry with MOSFET dosimeters to determine the dose along the field junction in a split beam technique. Radiotherapy and Oncology, 2003, 67, 351-357.	0.3	30
290	The importance of pre-treatment haemoglobin level in inoperablenon-small cell lung carcinoma treated with radical radiotherapy. Radiotherapy and Oncology, 2003, 67, 321-325.	0.3	30
291	Transition from a simple to a more advanced dose calculation algorithm for radiotherapy of non-small cell lung cancer (NSCLC): Implications for clinical implementation in an individualized dose-escalation protocol. Radiotherapy and Oncology, 2008, 88, 326-334.	0.3	30
292	Comparison Between Perfusion Computed Tomography and Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 77, 400-408.	0.4	30
293	Residual metabolic tumor activity after chemo-radiotherapy is mainly located in initially high FDG uptake areas in rectal cancer. Radiotherapy and Oncology, 2011, 99, 137-141.	0.3	30
294	No association between TGF- \hat{l}^21 polymorphisms and radiation-induced lung toxicity in a European cohort of lung cancer patients. Radiotherapy and Oncology, 2012, 105, 296-298.	0.3	30
295	Long-term survival of stage T4N0-1 and single station IIIA-N2 NSCLC patients treated with definitive chemo-radiotherapy using individualised isotoxic accelerated radiotherapy (INDAR). Radiotherapy and Oncology, 2014, 110, 482-487.	0.3	30
296	Combination of radiotherapy with the immunocytokine L19-IL2: Additive effect in a NK cell dependent tumour model. Radiotherapy and Oncology, 2015, 116, 438-442.	0.3	30
297	Pathway-based subnetworks enable cross-disease biomarker discovery. Nature Communications, 2018, 9, 4746.	5.8	30
298	The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1219-1235.	0.4	30
299	Genetic Variants Predict Optimal Timing of Radiotherapy to Reduce Side-effects in Breast Cancer Patients. Clinical Oncology, 2019, 31, 9-16.	0.6	30
300	A fully automatic artificial intelligence–based CT image analysis system for accurate detection, diagnosis, and quantitative severity evaluation of pulmonary tuberculosis. European Radiology, 2022, 32, 2188-2199.	2.3	30
301	Calibration of megavoltage coneâ€beam CT for radiotherapy dose calculations: Correction of cupping artifacts and conversion of CT numbers to electron density. Medical Physics, 2008, 35, 849-865.	1.6	29
302	When to Wait for More Evidence? Real Options Analysis in Proton Therapy. Oncologist, 2011, 16, 1752-1761.	1.9	29
303	Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage <scp>III</scp> nonâ€"small cell lung cancer. Cancer Medicine, 2013, 2, 916-924.	1.3	29
304	Individualized early death and long-term survival prediction after stereotactic radiosurgery for brain metastases of non-small cell lung cancer: Two externally validated nomograms. Radiotherapy and Oncology, 2017, 123, 189-194.	0.3	29
305	Human fibronectin extra domain B as a biomarker for targeted therapy in cancer. Molecular Oncology, 2020, 14, 1555-1568.	2.1	29
306	Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial. BMC Cancer, 2020, 20, 557.	1.1	29

#	Article	IF	Citations
307	Application of artificial intelligence in nuclear medicine and molecular imaging: a review of current status and future perspectives for clinical translation. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 4452-4463.	3.3	29
308	An "in silico―clinical trial comparing free breathing, slow and respiration correlated computed tomography in lung cancer patients. Radiotherapy and Oncology, 2006, 81, 73-80.	0.3	28
309	Development and evaluation of a cetuximab-based imaging probe to target EGFR and EGFRvIII. Radiotherapy and Oncology, 2007, 83, 326-332.	0.3	28
310	Advancing Clostridia to Clinical Trial: Past Lessons and Recent Progress. Cancers, 2016, 8, 63.	1.7	28
311	Time Trends in Nodal Volumes and Motion During Radiotherapy for Patients With Stage III Non-Small-Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 71, 139-144.	0.4	27
312	Evaluating Tumor Response of Non-Small Cell Lung Cancer Patients With 18F-Fludeoxyglucose Positron Emission Tomography: Potential for Treatment Individualization. International Journal of Radiation Oncology Biology Physics, 2015, 91, 376-384.	0.4	27
313	Optimization of tumor-targeted gene delivery by engineered attenuated Salmonella typhimurium. Anticancer Research, 2002, 22, 3261-6.	0.5	27
314	Radial gradient and radial deviation radiomic features from pre-surgical CT scans are associated with survival among lung adenocarcinoma patients. Oncotarget, 2017, 8, 96013-96026.	0.8	26
315	Improved effectiveness of stereotactic radiosurgery in large brain metastases by individualized isotoxic dose prescription: an in silico study. Strahlentherapie Und Onkologie, 2018, 194, 560-569.	1.0	26
316	Development and validation of a patient decision aid for prostate Cancer therapy: from paternalistic towards participative shared decision making. BMC Medical Informatics and Decision Making, 2019, 19, 130.	1.5	26
317	Novel fluorinated carbonic anhydrase IX inhibitors reduce hypoxia-induced acidification and clonogenic survival of cancer cells. Oncotarget, 2018, 9, 26800-26816.	0.8	25
318	Prognostic Assessment in High-Grade Soft-Tissue Sarcoma Patients: A Comparison of Semantic Image Analysis and Radiomics. Cancers, 2021, 13, 1929.	1.7	25
319	The application of a workflow integrating the variable reproducibility and harmonizability of radiomic features on a phantom dataset. PLoS ONE, 2021, 16, e0251147.	1.1	25
320	Clinical implementation of MOSFET detectors for dosimetry in electron beams. Radiotherapy and Oncology, 2006, 80, 288-295.	0.3	24
321	Regulation of Cited2 expression provides a functional link between translational and transcriptional responses during hypoxia. Radiotherapy and Oncology, 2007, 83, 346-352.	0.3	24
322	Preoperative CT-based radiomics combined with intraoperative frozen section is predictive of invasive adenocarcinoma in pulmonary nodules: a multicenter study. European Radiology, 2020, 30, 2680-2691.	2.3	24
323	Prognostic and Predictive Value of Integrated Qualitative and Quantitative Magnetic Resonance Imaging Analysis in Glioblastoma. Cancers, 2021, 13, 722.	1.7	24
324	Charged Particle and Conventional Radiotherapy: Current Implications as Partner for Immunotherapy. Cancers, 2021, 13, 1468.	1.7	24

#	Article	IF	Citations
325	Development and External Validation of Deep-Learning-Based Tumor Grading Models in Soft-Tissue Sarcoma Patients Using MR Imaging. Cancers, 2021, 13, 2866.	1.7	24
326	Preservation of parotid function with uncomplicated conformal radiotherapy. Radiotherapy and Oncology, 2002, 63, 203-11.	0.3	24
327	The deletion mutant EGFRvIII significantly contributes to stress resistance typical for the tumour microenvironment. Radiotherapy and Oncology, 2009, 92, 399-404.	0.3	23
328	Preclinical Assessment of Efficacy of Radiation Dose Painting Based on Intratumoral FDG-PET Uptake. Clinical Cancer Research, 2015, 21, 5511-5518.	3.2	23
329	Development of a virtual spacer to support the decision for the placement of an implantable rectum spacer for prostate cancer radiotherapy: Comparison of dose, toxicity and cost-effectiveness. Radiotherapy and Oncology, 2017, 125, 107-112.	0.3	23
330	Clustering of multi-parametric functional imaging to identify high-risk subvolumes in non-small cell lung cancer. Radiotherapy and Oncology, 2017, 125, 379-384.	0.3	23
331	Distinct radiation responses after in vitro mtDNA depletion are potentially related to oxidative stress. PLoS ONE, 2017, 12, e0182508.	1.1	23
332	The posterior cerebellum, a new organ at risk?. Clinical and Translational Radiation Oncology, 2018, 8, 22-26.	0.9	23
333	A novel co-culture assay to assess anti-tumor CD8+ T cell cytotoxicity via luminescence and multicolor flow cytometry. Journal of Immunological Methods, 2020, 487, 112899.	0.6	23
334	Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19–IL2 cures poorly immunogenic tumors when combined with radiotherapy. , 2021, 9, e001764.		23
335	Particle therapy in lung cancer: Where do we stand?. Cancer Treatment Reviews, 2008, 34, 259-267.	3.4	22
336	A qualitative synthesis of the evidence behind elective lymph node irradiation in oesophageal cancer. Radiotherapy and Oncology, 2014, 113, 166-174.	0.3	22
337	A phase 1 â€~window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients. BMC Cancer, 2016, 16, 644.	1.1	22
338	A novel concept for tumour targeting with radiation: Inverse dose-painting or targeting the "Low Drug Uptake Volume― Radiotherapy and Oncology, 2017, 124, 513-520.	0.3	22
339	Big Data in radiation therapy: challenges and opportunities. British Journal of Radiology, 2017, 90, 20160689.	1.0	22
340	New approach of delivering cytotoxic drugs towards CAIX expressing cells: A concept of dual-target drugs. European Journal of Medicinal Chemistry, 2017, 127, 691-702.	2.6	22
341	Genomics of non-small cell lung cancer (NSCLC): Association between CT-based imaging features and EGFR and K-RAS mutations in 122 patients—An external validation. European Journal of Radiology, 2019, 110, 148-155.	1.2	22
342	Proteomic analysis of gene expression following hypoxia and reoxygenation reveals proteins involved in the recovery from endoplasmic reticulum and oxidative stress. Radiotherapy and Oncology, 2007, 83, 340-345.	0.3	21

#	Article	IF	CITATIONS
343	Do We Have Enough Evidence to Implement Particle Therapy as Standard Treatment in Lung Cancer? A Systematic Literature Review. Oncologist, 2010, 15, 93-103.	1.9	21
344	A systematic methodology review of phase I radiation dose escalation trials. Radiotherapy and Oncology, 2010, 95, 135-141.	0.3	21
345	Improving decision making in larynx cancer by developing a decision aid: A mixed methods approach. Laryngoscope, 2019, 129, 2733-2739.	1.1	21
346	The "hype―of hydrops in classifying vestibular disorders: a narrative review. Journal of Neurology, 2020, 267, 197-211.	1.8	21
347	Is pulsed dose rate more damaging to spinal cord of rats than continuous low dose rate?. Radiotherapy and Oncology, 1997, 45, 39-47.	0.3	20
348	Dose recalculation in megavoltage cone-beam CT for treatment evaluation: Removal of cupping and truncation artefacts in scans of the thorax and abdomen. Radiotherapy and Oncology, 2010, 94, 359-366.	0.3	20
349	Is it time for tailored treatment of rectal cancer? From prescribing by consensus to prescribing by numbers. Radiotherapy and Oncology, 2012, 102, 1-3.	0.3	20
350	A Phase I Study of Concurrent Individualized, Isotoxic Accelerated Radiotherapy and Cisplatin–Vinorelbine–Cetuximab in Patients With Stage III Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2014, 9, 710-716.	0.5	20
351	[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 8-16.	3.3	20
352	Intensity-modulated proton therapy decreases dose to organs at risk in low-grade glioma patients: results of a multicentric $\langle i \rangle$ in silico $\langle i \rangle$ ROCOCO trial. Acta Oncol \tilde{A}^3 gica, 2019, 58, 57-65.	0.8	20
353	Design, synthesis, <i>inÂvitro</i> inhibition and toxicological evaluation of human carbonic anhydrases I, II and IX inhibitors in 5-nitroimidazole series. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 109-117.	2.5	20
354	MRI-Based Radiomics Analysis for the Pretreatment Prediction of Pathologic Complete Tumor Response to Neoadjuvant Systemic Therapy in Breast Cancer Patients: A Multicenter Study. Cancers, 2021, 13, 2447.	1.7	20
355	Does sucralfate reduce early side effects of pelvic radiation? A double-blind randomized trial. Radiotherapy and Oncology, 2002, 65, 105-108.	0.3	19
356	Prediction of residual metabolic activity after treatment in NSCLC patients. Acta $Oncol\tilde{A}^3$ gica, 2010, 49, 1033-1039.	0.8	19
357	Volume or Position Changes of Primary Lung Tumor During (Chemo-)Radiotherapy Cannot Be Used as a Surrogate for Mediastinal Lymph Node Changes: The Case for Optimal Mediastinal Lymph Node Imaging During Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2011, 79, 89-95.	0.4	19
358	A let-7 microRNA polymorphism in the KRAS 3′-UTR is prognostic in oropharyngeal cancer. Cancer Epidemiology, 2014, 38, 591-598.	0.8	19
359	Systematic analysis of 18F-FDG PET and metabolism, proliferation and hypoxia markers for classification of head and neck tumors. BMC Cancer, 2014, 14, 130.	1.1	19
360	Evofosfamide sensitizes esophageal carcinomas to radiation without increasing normal tissue toxicity. Radiotherapy and Oncology, 2019, 141, 247-255.	0.3	19

#	Article	IF	CITATIONS
361	Non-invasive imaging prediction of tumor hypoxia: A novel developed and externally validated CT and FDG-PET-based radiomic signatures. Radiotherapy and Oncology, 2020, 153, 97-105.	0.3	19
362	Fitter Mitochondria Are Associated With Radioresistance in Human Head and Neck SQD9 Cancer Cells. Frontiers in Pharmacology, 2020, $11,263$.	1.6	19
363	Biological Determinants of Chemo-Radiotherapy Response in HPV-Negative Head and Neck Cancer: A Multicentric External Validation. Frontiers in Oncology, 2019, 9, 1470.	1.3	19
364	A Simple but Highly Effective Approach to Evaluate the Prognostic Performance of Gene Expression Signatures. PLoS ONE, 2011, 6, e28320.	1.1	19
365	A non-invasive, automated diagnosis of Menière's disease using radiomics and machine learning on conventional magnetic resonance imaging: A multicentric, case-controlled feasibility study. Radiologia Medica, 2022, 127, 72-82.	4.7	19
366	The use of a comprehensive tumour xenograft dataset to validate gene signatures relevant for radiation response. Radiotherapy and Oncology, 2009, 92, 417-422.	0.3	18
367	Long-lasting antitumor effects provided by radiotherapy combined with the immunocytokine L19-IL2. Oncolmmunology, 2015, 4, e1021541.	2.1	18
368	Knowledge Graphs for COVID-19: An Exploratory Review of the Current Landscape. Journal of Personalized Medicine, 2021, 11, 300.	1.1	18
369	A comparison of early effects with two dose rates in brachytherapy of cervix carcinoma in a prospective randomised trial. European Journal of Cancer, 1994, 30, 312-320.	1.3	17
370	FDG-PET-CT for staging of high-risk breast cancer patients reduces the number of further examinations: A pilot study. Acta Oncol \tilde{A}^3 gica, 2010, 49, 185-191.	0.8	17
371	A phase l–II study on the combination of rapamycin and short course radiotherapy in rectal cancer. Radiotherapy and Oncology, 2015, 116, 214-220.	0.3	17
372	Imaging of tumour hypoxia and metabolism in patients with head and neck squamous cell carcinoma. Acta Oncol \tilde{A}^3 gica, 2015, 54, 1378-1384.	0.8	17
373	A validated tumor control probability model based on a metaâ€analysis of low, intermediate, and highâ€risk prostate cancer patients treated by photon, proton, or carbonâ€ion radiotherapy. Medical Physics, 2016, 43, 734-747.	1.6	17
374	Impact of <scp>SBRT</scp> fractionation in hypoxia dose painting â€" Accounting for heterogeneous and dynamic tumor oxygenation. Medical Physics, 2019, 46, 2512-2521.	1.6	17
375	Characterizing geometrical accuracy in clinically optimised 7T and 3T magnetic resonance images for high-precision radiation treatment of brain tumours. Physics and Imaging in Radiation Oncology, 2019, 9, 35-42.	1.2	17
376	Development and external validation of a non-invasive molecular status predictor of chromosome 1p/19q co-deletion based on MRI radiomics analysis of Low Grade Glioma patients. European Journal of Radiology, 2021, 139, 109678.	1.2	17
377	Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506. Molecular Cancer Therapeutics, 2021, 20, 2372-2383.	1.9	17
378	Mitochondrial Dysfunction Inhibits Hypoxia-Induced HIF-1α Stabilization and Expression of Its Downstream Targets. Frontiers in Oncology, 2020, 10, 770.	1.3	16

#	Article	IF	Citations
379	Can predicting COVID-19 mortality in a European cohort using only demographic and comorbidity data surpass age-based prediction: An externally validated study. PLoS ONE, 2021, 16, e0249920.	1.1	16
380	Exploiting the noise: improving biomarkers with ensembles of data analysis methodologies. Genome Medicine, 2012, 4, 84.	3.6	15
381	Optimal design and patient selection for interventional trials using radiogenomic biomarkers: A REQUITE and Radiogenomics consortium statement. Radiotherapy and Oncology, 2016, 121, 440-446.	0.3	15
382	Predicting tumor hypoxia in non-small cell lung cancer by combining CT, FDG PET and dynamic contrast-enhanced CT. Acta Oncol \tilde{A}^3 gica, 2017, 56, 1591-1596.	0.8	15
383	Implantation of a biodegradable rectum balloon implant: Tips, Tricks and Pitfalls. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2017, 43, 1033-1042.	0.7	15
384	<i>E. coli</i> nitroreductase NfsA is a reporter gene for non-invasive PET imaging in cancer gene therapy applications. Theranostics, 2020, 10, 10548-10562.	4.6	15
385	Tumour Size in Cancer of the Cervix. Acta Oncol \tilde{A}^3 gica, 1998, 37, 729-734.	0.8	14
386	In vivo animal functional MRI: Improved image quality with a body-adapted mold. Journal of Magnetic Resonance Imaging, 2002, 16, 224-227.	1.9	14
387	Can we optimize chemo-radiation and surgery in locally advanced stage III non-small cell lung cancer based on evidence from randomized clinical trials? A hypothesis-generating study. Radiotherapy and Oncology, 2009, 93, 389-395.	0.3	14
388	Blood glucose level normalization and accurate timing improves the accuracy of PET-based treatment response predictions in rectal cancer. Radiotherapy and Oncology, 2010, 95, 203-208.	0.3	14
389	An in silico comparison between margin-based and probabilistic target-planning approaches in head and neck cancer patients. Radiotherapy and Oncology, 2013, 109, 430-436.	0.3	14
390	Technical feasibility of integrating 7ÂT anatomical MRI in image-guided radiotherapy of glioblastoma: a preparatory study. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2016, 29, 591-603.	1.1	14
391	Nitroimidazole-based inhibitors DTP338 and DTP348 are safe for zebrafish embryos and efficiently inhibit the activity of human CA IX in <i>Xenopus</i> Occytes. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 1064-1073.	2.5	14
392	Hypoxia-activated prodrug derivatives of anti-cancer drugs: a patent review 2006 – 2021. Expert Opinion on Therapeutic Patents, 2022, 32, 1-12.	2.4	14
393	The Sulfamate Small Molecule CAIX Inhibitor S4 Modulates Doxorubicin Efficacy. PLoS ONE, 2016, 11, e0161040.	1.1	14
394	Integrating RAS Status into Prognostic Signatures for Adenocarcinomas of the Lung. Clinical Cancer Research, 2015, 21, 1477-1486.	3.2	13
395	Defining the hypoxic target volume based on positron emission tomography for image guided radiotherapy $\hat{a} \in \text{``the influence of the choice of the reference region and conversion function. Acta Oncol\hat{A}^3gica, 2017, 56, 819-825.$	0.8	13
396	What is the impact of innovation on output in healthcare with a special focus on treatment innovations in radiotherapy? A literature review. British Journal of Radiology, 2017, 90, 20170251.	1.0	13

#	Article	IF	Citations
397	Combining hypoxia-activated prodrugs and radiotherapy in silico: Impact of treatment scheduling and the intra-tumoural oxygen landscape. PLoS Computational Biology, 2020, 16, e1008041.	1.5	13
398	Clostridium to treat cancer: dream or reality?. Annals of Translational Medicine, 2015, 3, S21.	0.7	13
399	High dose rate and flattening filter free irradiation can be safely implemented in clinical practice. International Journal of Radiation Biology, 2015, 91, 778-785.	1.0	12
400	Is selective nodal irradiation in non-small cell lung cancer still safe when using IMRT? Results of a prospective cohort study. Radiotherapy and Oncology, 2016, 121, 322-327.	0.3	12
401	[18F]-HX4 PET/CT hypoxia in patients with squamous cell carcinoma of the head and neck treated with chemoradiotherapy: Prognostic results from two prospective trials. Clinical and Translational Radiation Oncology, 2020, 23, 9-15.	0.9	12
402	A Prospectively Validated Prognostic Model for Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck Based on Radiomics of Computed Tomography Images. Cancers, 2021, 13, 3271.	1.7	12
403	Privacy preserving distributed learning classifiers – Sequential learning with small sets of data. Computers in Biology and Medicine, 2021, 136, 104716.	3.9	12
404	Machine learning for grading and prognosis of esophageal dysplasia using mass spectrometry and histological imaging. Computers in Biology and Medicine, 2021, 138, 104918.	3.9	12
405	Effect of TNP-470 (AGM-1470) on the Growth of Rat Rhabdomyosarcoma Tumors of Different Sizes. Cancer Investigation, 2001, 19, 35-40.	0.6	11
406	Health related quality of life assessment instruments: A prospective study on preference and acceptability among cancer patients referred for radiotherapy. European Journal of Cancer, 2005, 41, 2250-2256.	1.3	11
407	Formation of lysine 63-linked poly-ubiquitin chains protects human lung cells against benzo[a]pyrene-diol-epoxide-induced mutagenicity. DNA Repair, 2007, 6, 852-862.	1.3	11
408	Survival Prediction in Lung Cancer Treated with Radiotherapy: Bayesian Networks vs. Support Vector Machines in Handling Missing Data., 2009,,.		11
409	Repeated Positron Emission Tomography-Computed Tomography and Perfusion-Computed Tomography Imaging in Rectal Cancer: Fluorodeoxyglucose Uptake Corresponds With Tumor Perfusion. International Journal of Radiation Oncology Biology Physics, 2012, 82, 849-855.	0.4	11
410	Quantification of CT-assessed radiation-induced lung damage in lung cancer patients treated with or without chemotherapy and cetuximab. Acta Oncol ${\rm A}^3$ gica, 2016, 55, 156-162.	0.8	11
411	Quality assessment of positron emission tomography scans: recommendations for future multicentre trials. Acta Oncológica, 2017, 56, 1459-1464.	0.8	11
412	Ano-rectal wall dose-surface maps localize the dosimetric benefit of hydrogel rectum spacers in prostate cancer radiotherapy. Clinical and Translational Radiation Oncology, 2019, 14, 17-24.	0.9	11
413	Nitroglycerin as a radiosensitizer in non-small cell lung cancer: Results of a prospective imaging-based phase II trial. Clinical and Translational Radiation Oncology, 2020, 21, 49-55.	0.9	11
414	A Dutch phase III randomized multicenter trial: whole brain radiotherapy versus stereotactic radiotherapy for 4–10 brain metastases. Neuro-Oncology Advances, 2021, 3, vdab021.	0.4	11

#	Article	IF	Citations
415	Role of hypoxia-activated prodrugs in combination with radiation therapy: An <i>in silico</i> approach. Mathematical Biosciences and Engineering, 2019, 16, 6257-6273.	1.0	11
416	Palliative chest irradiation in sitting position in patients with bulky advanced lung cancer. Radiotherapy and Oncology, 2006, 79, 285-287.	0.3	10
417	The influence of gastric filling instructions on dose delivery in patients with oesophageal cancer: A prospective study. Radiotherapy and Oncology, 2015, 117, 442-447.	0.3	10
418	Evidence on the efficacy of primary radiosurgery or stereotactic radiotherapy for drug-resistant non-neoplastic focal epilepsy in adults: A systematic review. Seizure: the Journal of the British Epilepsy Association, 2018, 55, 83-92.	0.9	10
419	Efficient Secretion of Murine IL-2 From an Attenuated Strain of Clostridium sporogenes, a Novel Delivery Vehicle for Cancer Immunotherapy. Frontiers in Microbiology, 2021, 12, 669488.	1.5	10
420	Phased Versus Midventilation Attenuation-Corrected Respiration-Correlated PET for Patients with Non-Small Cell Lung Cancer. Journal of Nuclear Medicine Technology, 2009, 37, 208-214.	0.4	9
421	A framework based on hidden Markov trees for multimodal <scp>PET</scp> / <scp>CT</scp> image coâ€segmentation. Medical Physics, 2017, 44, 5835-5848.	1.6	9
422	Cycle-Consistent Generative Adversarial Network: Effect on Radiation Dose Reduction and Image Quality Improvement in Ultralow-Dose CT for Evaluation of Pulmonary Tuberculosis. Korean Journal of Radiology, 2021, 22, 983.	1.5	9
423	Use of an optimised enzyme/prodrug combination for Clostridia directed enzyme prodrug therapy induces a significant growth delay in necrotic tumours. Cancer Gene Therapy, 2022, 29, 178-188.	2.2	9
424	Deciphering the glioblastoma phenotype by computed tomography radiomics. Radiotherapy and Oncology, 2021, 160, 132-139.	0.3	9
425	Beyond automatic medical image segmentationâ€"the spectrum between fully manual and fully automatic delineation. Physics in Medicine and Biology, 2022, 67, 12TR01.	1.6	9
426	Should Patient Setup in Lung Cancer Be Based on the Primary Tumor? An Analysis of Tumor Coverage and Normal Tissue Dose Using Repeated Positron Emission Tomography/Computed Tomography Imaging. International Journal of Radiation Oncology Biology Physics, 2012, 82, 379-385.	0.4	8
427	How efficient is translational research in radiation oncology? The example of a large Dutch academic radiation oncology department. British Journal of Radiology, 2016, 89, 20160129.	1.0	8
428	Multistate Statistical Modeling. Medical Decision Making, 2016, 36, 86-100.	1.2	8
429	Prospective validation of pathologic complete response models in rectal cancer: Transferability and reproducibility. Medical Physics, 2017, 44, 4961-4967.	1.6	8
430	Non-linear conversion of HX4 uptake for automatic segmentation of hypoxic volumes and dose prescription. Acta $Oncol\tilde{A}^3$ gica, 2018, 57, 485-490.	0.8	8
431	Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology. European Journal of Cancer, 2019, 114, 128-136.	1.3	8
432	Implementing Systems Modelling and Molecular Imaging to Predict the Efficacy of BCL-2 Inhibition in Colorectal Cancer Patient-Derived Xenograft Models. Cancers, 2020, 12, 2978.	1.7	8

#	Article	IF	CITATIONS
433	Hypoxia-Activated Prodrug Derivatives of Carbonic Anhydrase Inhibitors in Benzenesulfonamide Series: Synthesis and Biological Evaluation. Molecules, 2020, 25, 2347.	1.7	8
434	Development of a Management Algorithm for Acute and Chronic Radiation Urethritis and Cystitis. Urologia Internationalis, 2022, 106, 63-74.	0.6	8
435	Reproducibility of CT-Based Hepatocellular Carcinoma Radiomic Features across Different Contrast Imaging Phases: A Proof of Concept on SORAMIC Trial Data. Cancers, 2021, 13, 4638.	1.7	8
436	In vivo optical imaging of MMP2 immuno protein antibody: tumor uptake is associated with MMP2 activity. Scientific Reports, 2016, 6, 22198.	1.6	8
437	Diagnosis of Idiopathic Pulmonary Fibrosis in High-Resolution Computed Tomography Scans Using a Combination of Handcrafted Radiomics and Deep Learning. Frontiers in Medicine, 0, 9, .	1.2	8
438	Effectiveness of surgery and individualized high-dose hyperfractionated accelerated radiotherapy on survival in clinical stage I non-small cell lung cancer. A propensity score matched analysis. Radiotherapy and Oncology, 2010, 97, 413-417.	0.3	7
439	Radiotherapy with curative intent for lung cancer: A continuing success story. Radiotherapy and Oncology, 2011, 101, 237-239.	0.3	7
440	Probabilistic evaluation of target dose deterioration in dose painting by numbers for stage II/III lung cancer. Practical Radiation Oncology, 2015, 5, e375-e382.	1.1	7
441	What Level of Accuracy Is Achievable for Preclinical Dose Painting Studies on a Clinical Irradiation Platform?. Radiation Research, 2015, 183, 501.	0.7	7
442	What is the degree of innovation routinely implemented in Dutch radiotherapy centres? A multicentre cross-sectional study. British Journal of Radiology, 2016, 89, 20160601.	1.0	7
443	Toxicity of L19-Interleukin 2 Combined with Stereotactic Body Radiation Therapy: A Phase 1 Study. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1421-1430.	0.4	7
444	Reply to Orlhac, F.; Buvat, I. Comment on "lbrahim et al. The Effects of In-Plane Spatial Resolution on CT-Based Radiomic Features' Stability with and without ComBat Harmonization. Cancers 2021, 13, 1848― Cancers, 2021, 13, 3080.	1.7	7
445	Exploratory Radiomic Analysis of Conventional vs. Quantitative Brain MRI: Toward Automatic Diagnosis of Early Multiple Sclerosis. Frontiers in Neuroscience, 2021, 15, 679941.	1.4	7
446	An experimental evaluation of three preoperative radiation regimens for resectable rectal cancer. Annals of Surgical Oncology, 2002, 9, 292-297.	0.7	6
447	Individualized Positron Emission Tomography–Based Isotoxic Accelerated Radiation Therapy Is Cost-Effective Compared With Conventional Radiation Therapy: A Model-Based Evaluation. International Journal of Radiation Oncology Biology Physics, 2015, 91, 857-865.	0.4	6
448	Development of an isotoxic decision support system integrating genetic markers of toxicity for the implantation of a rectum spacer. Acta Oncol \tilde{A}^3 gica, 2018, 57, 1499-1505.	0.8	6
449	Deep Learning–based Automatic Lung Segmentation on Multiresolution CT Scans from Healthy and Fibrotic Lungs in Mice. Radiology: Artificial Intelligence, 2022, 4, e210095.	3.0	6
450	A Handcrafted Radiomics-Based Model for the Diagnosis of Usual Interstitial Pneumonia in Patients with Idiopathic Pulmonary Fibrosis. Journal of Personalized Medicine, 2022, 12, 373.	1.1	6

#	Article	IF	CITATIONS
451	An externally validated fully automated deep learning algorithm to classify COVID-19 and other pneumonias on chest computed tomography. ERJ Open Research, 2022, 8, 00579-2021.	1.1	6
452	Carbonic anhydrase inhibitors: Gd(iii) complexes of DOTA- and TETA-sulfonamide conjugates targeting the tumor associated carbonic anhydrase isozymes IX and XII. New Journal of Chemistry, 2010, 34, 2139.	1.4	5
453	A biodegradable rectal balloon implant to protect the rectum during prostate cancer radiotherapy for a patient with active Crohn's disease. Technical Innovations and Patient Support in Radiation Oncology, 2018, 6, 1-4.	0.6	5
454	Multi-Scale Modeling and Oxygen Impact on Tumor Temporal Evolution: Application on Rectal Cancer During Radiotherapy. IEEE Transactions on Medical Imaging, 2018, 37, 871-880.	5.4	5
455	Towards a Clinical Decision Support System for External Beam Radiation Oncology Prostate Cancer Patients: Proton vs. Photon Radiotherapy? A Radiobiological Study of Robustness and Stability. Cancers, 2018, 10, 55.	1.7	5
456	Limitations of Only Reporting the Odds Ratio in the Age of Precision Medicine: A Deterministic Simulation Study. Frontiers in Medicine, 2021, 8, 640854.	1.2	5
457	Artificial intelligence in oncology. , 2021, , 361-381.		4
458	CT Reconstruction Kernels and the Effect of Pre- and Post-Processing on the Reproducibility of Handcrafted Radiomic Features. Journal of Personalized Medicine, 2022, 12, 553.	1.1	4
459	MaasPenn Radiomics Reproducibility Score: A Novel Quantitative Measure for Evaluating the Reproducibility of CT-Based Handcrafted Radiomic Features. Cancers, 2022, 14, 1599.	1.7	4
460	MODEL-BASED COST-EFFECTIVENESS OF CONVENTIONAL AND INNOVATIVE CHEMO-RADIATION IN LUNG CANCER. International Journal of Technology Assessment in Health Care, 2017, 33, 681-690.	0.2	3
461	Performing clinical 18F-FDG-PET/MRI of the mediastinum optimising a dedicated, patient-friendly protocol. Nuclear Medicine Communications, 2019, 40, 815-826.	0.5	3
462	Covid19Risk.ai: An Open Source Repository and Online Calculator of Prediction Models for Early Diagnosis and Prognosis of Covid-19. BioMed, 2021, 1, 41-49.	0.6	3
463	Improving and Externally Validating Mortality Prediction Models for COVID-19 Using Publicly Available Data. BioMed, 2022, 2, 13-26.	0.6	3
464	Predicting Adverse Radiation Effects in Brain Tumors After Stereotactic Radiotherapy With Deep Learning and Handcrafted Radiomics. Frontiers in Oncology, 0, 12, .	1.3	3
465	How to measure innovation in radiotherapy: an application of the Delphi method. Journal of Hospital Administration, 2015, 4, 14.	0.0	2
466	The transcriptomic profile of ovarian cancer grading. Cancer Medicine, 2015, 4, 56-64.	1.3	2
467	Quality of life among patients with 4 to 10 brain metastases after treatment with whole-brain radiotherapy vs. stereotactic radiotherapy: a phase III, randomized, Dutch multicenter trial. Annals of Palliative Medicine, 2022, 11, 1197-1209.	0.5	2
468	Clostridium-Mediated Transfer of Therapeutic Proteins to Solid Tumors., 2003,, 527-546.		1

#	Article	IF	CITATIONS
469	P3-046: Personalized High-Dose Continuous Hyperfractionated Accelerated Radiotherapy (HI-CHART) of non-small cell lung cancer (NSCLC) based on normal tissue constraints: a prospective clinical trial. Journal of Thoracic Oncology, 2007, 2, S626.	0.5	1
470	Edmond-Philippe Malaise (1930-2013): A Lifetime of Perseverance Leads to the Cellular Definition of Intrinsic Radiosensitivity. International Journal of Radiation Oncology Biology Physics, 2014, 88, 1215-1217.	0.4	1
471	Reply to "COVID-19 prediction models should adhere to methodological and reporting standards― European Respiratory Journal, 2020, 56, 2002918.	3.1	1
472	Lymph node response to chemoradiotherapy in oesophageal cancer patients: relationship with radiotherapy fields. Esophagus, 2021, 18, 100-110.	1.0	1
473	Modeling-Based Decision Support System for Radical Prostatectomy Versus External Beam Radiotherapy for Prostate Cancer Incorporating an In Silico Clinical Trial and a Cost–Utility Study. Cancers, 2021, 13, 2687.	1.7	1
474	Late Breaking Abstract - Development and validation of an automated radiomic CT signature for detecting? COVID-19. , 2020, , .		1
475	Why determine only the total prostate-specific antigen, if the free-to-total ratio contains the information?. Annals of Clinical Biochemistry, 2008, 45, 270-274.	0.8	0
476	In response to the "Letter to the Editor―by Borst et al.: Dyspnea evaluation after high-dose radiotherapy in patients with NSCLC. Radiotherapy and Oncology, 2009, 91, 461-462.	0.3	0
477	Interview: Lung cancer: a very challenging disease. Lung Cancer Management, 2013, 2, 461-465.	1.5	O
478	[I232] Radiomics: Transforming standard imaging into mineable data related to biology. Physica Medica, 2018, 52, 87.	0.4	0
479	SP-0687 Combining Radiotherapy with Immunotherapy: focus on immunocytokines. Radiotherapy and Oncology, 2019, 133, S358-S359.	0.3	0
480	OC-0407 CT-based Radiomics for Risk Stratification in Prostate Cancer. Radiotherapy and Oncology, 2019, 133, S209.	0.3	0
481	PO-0855 Development and Validation of a Prostate Cancer Patient Decision Aid: Towards Participative Medicine. Radiotherapy and Oncology, 2019, 133, S450-S451.	0.3	O
482	NIMG-65. PREDICTING PROGNOSIS AND CANCER HOTSPOT MUTATIONS USING QUALITATIVE MR IMAGING ANALYSIS IN GLIOBLASTOMA. Neuro-Oncology, 2019, 21, vi176-vi176.	0.6	0
483	El papel emergente de la radiómica en la EPOC y el cáncer de pulmón. Karger Kompass NeumologÃa, 2020, , 46-53.	0.0	O
484	Radiomics based on baseline DCE-MRI is predictive of tumor pathological complete response to neoadjuvant systemic therapy in breast cancer patients. European Journal of Surgical Oncology, 2020, 46, e23.	0.5	0
485	The growing significance of smartphone apps in data-driven clinical decision-making: Challenges and pitfalls., 2021,, 173-182.		0
486	Biomarkers for Hypoxia, HPVness, and Proliferation from Imaging Perspective., 2021, , 13-20.		0

#	Article	IF	CITATIONS
487	Radiomics: Transforming Standard Imaging into Mineable Data for Diagnostic and Theragnostic Applications. , 2021, , .		O
488	Abstract IA-07: Radiomics: Transforming standard imaging into mineable data for diagnostic and the ragnostic applications. , $2021, , .$		0
489	How Should Data Be Shared and Rapid Learning Health Care Promoted?. , 2012, , 355-364.		0
490	Bacterial Systems for Tumor-Specific Gene Therapy. , 2005, , 393-404.		0
491	EXTH-30. EXPANDING THE UTILITY OF PRE-CLINICAL CONTRAST ENHANCED CT (CE-CT) FOR TUMOR DETECTION IN ORTHOTOPIC GBM MODELS USING RADIOMICS. Neuro-Oncology, 2020, 22, ii93-ii93.	0.6	0
492	Title is missing!. , 2020, 15, e0232639.		0
493	Title is missing!. , 2020, 15, e0232639.		O
494	Title is missing!. , 2020, 15, e0232639.		0
495	Title is missing!. , 2020, 15, e0232639.		O